In vitro activities of 11 fluoroquinolones against 226 Campylobacter jejuni strains isolated from Finnish patients, with special reference to ciprofloxacin resistance

Journal of Antimicrobial Chemotherapy

Volumn 56, Issue 6, 2005, Pages 1134-1138

  Lehtopolku, Mirva ^a,b   Hakanen, Antti J ^a,b   Siitonen, Anja ^a   Huovinen, Pentti ^a   Kotilainen, Pirkko ^a,b  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Campylobacter spp.; Drug resistance; Quinolones

Indexed keywords

ANTIINFECTIVE AGENT; CIPROFLOXACIN; CLINAFLOXACIN; ENROFLOXACIN; GATIFLOXACIN; GEMIFLOXACIN; LEVOFLOXACIN; LOMEFLOXACIN; MOXIFLOXACIN; NORFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SITAFLOXACIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; CAMPYLOBACTER JEJUNI; CONTROLLED STUDY; DRUG EFFICACY; FINLAND; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN;

ANTI-BACTERIAL AGENTS; CAMPYLOBACTER INFECTIONS; CAMPYLOBACTER JEJUNI; CIPROFLOXACIN; DRUG RESISTANCE, BACTERIAL; FECES; FINLAND; FLUOROQUINOLONES; GASTROENTERITIS; HOSPITALS; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 29444438308     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dki380     Document Type: Article

References (10)

1. Hakanen A, Jousimies-Somer H, Siitonen A et al. Fluoroquinolone resistance in Campylobacter jejuni isolates in travelers returning to Finland: Association of ciprofloxacin resistance to travel destination. Emerg Infect Dis 2003; 9: 267-70.
2. Engberg J, Aarestrup FM, Taylor DE et al. Quinolone and macrolide resistance in Campylobacter jejuni and C. coli. resistance mechanisms and trends in human isolates. Emerg Infect Dis 2001; 7: 24-34.
3. Milatovic D, Schmitz FJ, Brisse S et al. In vitro activities of sitafloxacin (DU-6859a) and six other fluoroquinolones against 8,796 clinical bacterial isolates. Antimicrob Agents Chemother 2000; 44: 1102-7.
4. Hakanen A, Jalava J, Kotilainen P et al. gyrA polymorphism in Campylobacter jejuni: Detection of gyrA mutations in 162 C.jejuni isolates by single-strand conformation polymorphism and DNA sequencing. Antimicrob Agents Chemother 2002; 46: 2644-7.
5. Hakanen AJ, Lehtopolku M, Siitonen A et al. Multidrug resistance in Campylobacter jejuni strains collected from Finnish patients during 1995-2000. J Antimicrob Chemother 2003; 52; 1035-9.
6. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing. Fourteenth Informational Supplement: Approved standard M2-A8 and M7-A6. NCCLS, Wayne, PA, USA, 2004.
7. Tomayko J, Korten V, Murray B. DU-6859a, a new fluoroquinolone agent. Comparative in vitro activity against enteric pathogens and multiresistant outpatient Escherichia coli. Diagn Microbiol Infect Dis 1994; 20: 45-7.
8. Bauernfeind A. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J Antimicrob Chemother 1997; 40: 639-51.
9. Deguchi T, Yasuda M, Kawamura T et al. Improved antimicrobial activity of DU-6859a, a new fluoroquinolone, against quinolone-resistant Klebsiella pneumoniae and Enterobacter cloacae isolates with alterations in GyrA and ParC proteins. Antimicrob Agents Chemother 1997; 41: 2544-6.
10. Deguchi T, Yasuda M, Nakano M et al. Antimicrobial activity of a new fluoroquinolone, DU-6859a, against quinolone-resistant clinical isolates of Neisseria gonorrhoeae with genetic alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV. J Antimicrob Chemother 1997; 39: 247-9.